Full Breakdown
FDA Reverses Stance, Clears Path for UniQure’s Huntington’s Gene-Therapy
6/18/2026, 4:53:49 AM
Regulatory Reversal Opens BLA Path
On 17 June 2026 the U.S. Food and Drug Administration announced that the three-year analysis from UniQure’s Phase I/II study of AMT-130 will serve as the primary evidence for a Biologics License Application (BLA) under the accelerated-approval pathway. The agency will work with the company to finalize a confirmatory study before the filing, which UniQure plans to submit in the third quarter of 2026. This decision overturns the agency’s March 2026 position that a new sham-surgery trial was required.
Background & Context
Huntington’s disease (HD) is a fatal, inherited neurodegenerative disorder with no approved disease-modifying therapies. AMT-130 is a one-time gene-therapy that delivers an adeno-associated virus carrying micro-RNA to silence the mutant huntingtin (HTT) gene in the striatum. Early trials raised ethical concerns because a placebo-controlled arm would have required sham brain surgery—drilling burr holes without delivering the therapeutic vector.
Key Figures & Groups
- UniQure BV – Dutch biotech developer of AMT-130; CEO Matt Kapusta and chief medical officer (unnamed).
- Vinay Prasad – Former head of the FDA’s gene-therapy review office; advocated for a sham-surgery control.
- Marty Makary – Former FDA commissioner who publicly questioned the therapy’s benefit.
- Kyle Diamantas – Acting FDA commissioner who met rare-disease advocates in June 2026.
- Congressman Jake Auchincloss – Criticized Prasad’s alleged rule violations.
Data & Statistics
- Phase I/II trial enrolled 29 participants; 12 received the high dose of AMT-130.
- At three years, the high-dose cohort showed a 75 % reduction in disease-progression rate versus matched external controls from the Enroll-HD natural-history database.
- UniQure’s share price rose 70-80 % after the FDA reversal (peaking at $49.49 in pre-market trading).
- The therapy holds Regenerative Medicine Advanced Therapy, Breakthrough Therapy, and Fast-Track designations.
Official Statements & Responses
The FDA emphasized its “commitment to gold-standard science” while acknowledging the need for a post-approval confirmatory study, preferably using a concurrent standard-of-care control rather than sham surgery. UniQure’s leadership expressed gratitude for the agency’s “genuine commitment to addressing the unmet need of Americans living with Huntington’s disease” and confidence that the existing data “provide a solid basis for accelerated approval.”
Criticism & Opposition
Former FDA officials and some investors criticized AMT-130. Prasad and Makary argued that the external-control design lacked rigor and that the therapy showed “no benefit.” A senior regulator previously labeled the product a “failed product.” Ethical objections to a sham-surgery control were voiced by patient groups and European regulators, who deemed such a design “unethical.”
Conflicting Reports & Gaps
- Evidence sufficiency: In November 2025 the FDA deemed the Phase I/II data inadequate; by June 2026 it accepted the same data for a BLA.
- Timeline: UniQure originally targeted a Q1 2026 filing; the revised plan pushes the submission to Q3 2026.
- Confirmatory study design: The agency has not finalized whether the post-approval trial will use a standard-of-care arm, a concurrent control, or another approach.
Verbatim Quotes
- “The FDA "remains committed to working with UniQure to identify a regulatory pathway that serves patients with Huntington's disease and their families, while upholding the agency's commitment to gold-standard science," the official said in a statement.” — FDA spokesperson, 17 June 2026.
- “This is obviously a ~180 from FDA,” — Stifel analyst, 17 June 2026.
- “The consistency and strength of the clinical data generated to date give us great confidence in the product's potential to make a meaningful difference for patients.” — Matt Kapusta, CEO, UniQure.
- “At the end of the randomization period, it was found no benefit, and yet this is one of the drugs that we were pressured to approve.” — Marty Makary, former FDA commissioner.
- “failed product.” — Senior FDA regulator (quoted in Reuters, 17 June 2026).
What’s Next
UniQure will file the BLA in Q3 2026 and work with the FDA to lock in the confirmatory study design, likely a standard-of-care control. If the BLA is accepted, the confirmatory trial must verify the 75 % slowing of progression; failure could trigger market withdrawal. Parallel submissions to the U.K. Medicines and Healthcare products Regulatory Agency are slated for late 2026, expanding the global pursuit of the first disease-modifying HD therapy.
